Abstract
Abstract
Background/aims
In order to make the centers more attractive to trial sponsors, in recent years, some research institutions around the world have pursued projects to reorganize the pathway of trial activation, developing new organizational models to improve the activation process and reduce its times.
This study aims at analyzing and reorganizing the start-up phase of trials conducted at the Research and Innovation Department (DAIRI) of the Public Hospital of Alessandria (Italy).
Methods
A project was carried out to reorganize the trial authorization process at DAIRI by involving the three facilities responsible for this pathway: clinical trial center (CTC), ethics committee secretariat (ESC), and administrative coordination (AC).
Lean Thinking methodology was used with the A3 report tool, and the analysis was carried out by monitoring specific key performance indicators, derived from variables representing highlights of the trials’ activation pathway.
The project involved phases of analysis, implementation of identified countermeasures, and monitoring of timelines in eight 4-month periods.
The overall mean and median values of studies activation times were calculated as well as the average times for each facility involved in the process.
Results
In this study, 298 studies both sponsored by research associations and industry with both observational and interventional study design were monitored.
The mean trial activation time was reduced from 218 days before the project to 56 days in the last period monitored.
From the first to the last monitoring period, each facility involved achieved at least a halving of the average time required to carry out its activities in the clinical trials’ activation pathway (CTC: 55 days vs 23, ECS: 25 days vs 8, AC 29 days vs 10).
Average activation time for studies with agreement remains longer than those without agreement (100 days vs. 46).
Conclusions
The reorganization project emphasized the importance of having clinical and administrative staff specifically trained on the trial activation process.
This reorganization led to the development of a standard operating procedure and a tool to monitor the time (KPIs of the process) that can also be implemented in other clinical centers.
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Gehring M, Jommi C, Tarricone R, et al. Towards a more competitive Italy in clinical research: the Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiol Biostat Public Health. 2015;12(1):1–9.
2. Colcera S, Rizzini P. Indagine sul processo di valutazione degli studi clinici e relative tempistiche autorizzative in alcuni Paesi europei. Tendenze nuove. 2016;1:75–82.
3. Guideline for good clinical practice E6(R2). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf. Accesed 6 July 2023.
4. Miller T, Sevastita V, Chaitt D, et al. Protocol development program: a novel approach to overcoming barriers to clinical research. Monitor (Assoc Clin Pharmacol). 2013;27(1):54–61.
5. Duley L, Gillman A, Duggan M, et al. What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK. Trials. 2018;19(1):1–7.